News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Shorts

Comparing HIFU To Surgery and SBRT in Localized Prostate Cancer

3 months ago

by

Mina Fam, MD

Benjamin Cooper, MD, spoke with CancerNetwork® about the mechanism of JNJ-1900, an investigational nanoparticle radioenhancer, as a treatment for patients with unresectable stage III non–small cell lung cancer as part of the phase 2 CONVERGE trial (NCT06667908).

Novel Radioenhancer May Help Prevent Disease Recurrence in Stage III NSCLC

3 months ago

by

Benjamin Cooper, MD

Why Are Younger Women Getting Diagnosed With Breast Cancer?

Why Are Younger Women Getting Diagnosed With Breast Cancer?

3 months ago

by

Shari B. Goldfarb, MD

In a conversation with CancerNetwork®, Nicole Lamanna, MD, discussed the potential role of minimal residual disease (MRD) as a tool for informing treatment strategies in chronic lymphocytic leukemia (CLL) management.

Can MRD Influence Therapy Duration in Chronic Lymphocytic Leukemia?

3 months ago

by

Nicole Lamanna, MD

In a discussion with CancerNetwork®, Nicolas Girard, MD, PhD, highlighted findings from the PALOMA-2 study (NCT05498428) that he and colleagues presented at the 2026 European Lung Cancer Congress.

PALOMA-2 Shows Benefits of Subcutaneous Amivantamab in EGFR+ NSCLC

3 months ago

by

Nicolas Girard, MD, PhD

Jeff P. Sharman, MD, identified ways to help expand access to bispecific antibodies among patients with diffuse large B-cell lymphoma.

Overcoming Institutional Barriers to Bispecific Antibody Access in DLBCL

4 months ago

by

Jeff P. Sharman, MD

Karie Runcie, MD, provided next steps for improving outcomes in genitourinary cancers, specifically related to kidney cancer.

Leveraging Neoadjuvant Strategies to Bolster Cure Rates in Kidney Cancer

4 months ago

by

Karie Danielle Keera Runcie, MD

A recent study that found 10.6% of patients developed a new mental health disorder within 1 year of their cancer diagnosis.

What New Tools Can Improve Mental Health Screening in Cancer Care?

4 months ago

by

Julian C. Hong, MD, MS

Karie Runcie, MD, highlighted research she conducted as part of the phase 2 Cyto-KIK trial, a single-arm study assessing cabozantinib and nivolumab in metastatic kidney cancer prior to cytoreductive nephrectomy.

Cabozantinib Combo Displays Feasibility in Metastatic Kidney Cancer Group

4 months ago

by

Karie Danielle Keera Runcie, MD

Oxybutynin offered comparable ‘speed-to-relief’ vs comparators among patients experiencing hot flashes while on androgen deprivation therapy for prostate cancer, according to Bradley J. Stish, MD.

Offering Rapid Relief of Treatment-Emergent Hot Flashes in Prostate Cancer

4 months ago

by

Bradley J. Stish, MD

$Following the FDA approval of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory multiple myeloma, María-Victoria Mateos, MD, PhD, spoke with CancerNetwork® about how findings from the phase 3 MajesTEC-3 trial (NCT05083169) support the regimen’s clinical utility.$

Teclistamab/Daratumumab: An Exciting Combination in R/R Multiple Myeloma

4 months ago

by

Maria-Victoria Mateos, MD, PhD

Despite accounting for less than 1% of prostate cancer diagnoses, neuroendocrine prostate cancer (NEPC) is associated with suboptimal outcomes in the space, according to Rahul Aggarwal, MD.

Highlighting an Unmet Need in Neuroendocrine Prostate Cancer

4 months ago

by

Rahul R. Aggarwal, MD

The phase 3 CHALLENGE trial established a significant survival advantage among patients with colorectal cancer who underwent a structured exercise program, according to Linda Carlson, PhD, RPsych.

Could Exercise Be Prescribed as a Standard of Care for Cancer Treatment?

4 months ago

by

Linda E. Carlson, PhD

In a discussion with CancerNetwork®, Guenther Koehne, MD, highlighted the rapid development of therapeutic options in the multiple myeloma field, which has seen an increase in novel immunotherapies and a decrease in the use of chemotherapy.

Is a Functional Cure Possible in Multiple Myeloma Therapy?

4 months ago

by

Guenther Koehne, MD

Care Coordination Experiences in Breast Cancer

Care Coordination Experiences in Breast Cancer

4 months ago

by

Nicole Arrato, PhD

Joaquim Bellmunt, MD, PhD, discussed the emergence of EVP as a standard of care regardless of fitness among all cisplatin-eligible MIBC populations.

Affirming Enfortumab Vedotin/Pembrolizumab as a Standard Across MIBC Groups

4 months ago

by

Joaquim Bellmunt, MD, PhD

In a conversation with CancerNetwork®, Nicolaus Kröger, MD, detailed how JAK inhibition can work in tandem with transplantation to improve outcomes among patients with myelofibrosis.

JAK Inhibitors May Improve Transplantation Outcomes in Myelofibrosis

4 months ago

by

Nicolaus Kröger, MD

Joy Li, MD, discussed findings from a retrospective analysis of patients treated with enfortumab vedotin with or without pembrolizumab in the adjuvant setting for at least 2 cycles of treatment at the 2026 ASCO GU Symposium.

Should You Discontinue Therapy for Urothelial Carcinoma During Toxicity?

4 months ago

by

Joy Li, MD

Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction

Study Finds 80% of Young Cancer Survivors Face Sexual Dysfunction

4 months ago

by

Chiara Acquati, PhD, LMSW, FAOSW

Benjamin Garmezy, MD, discussed safe management practices for treatment-emergent adverse effects (TEAEs) with MRT-2359 plus enzalutamide in the treatment of androgen receptor ligand-binding domain-mutated metastatic castration-resistant prostate cancer.

Examining Optimal Management Strategies for MRT-2359 in LBD-Mutant CRPC

4 months ago

by

Benjamin Garmezy, MD

When Do New Mental Health Disorders Occur Most in Patients with Cancer?

When Do New Mental Health Disorders Occur Most in Patients with Cancer?

4 months ago

by

Julian C. Hong, MD, MS

Chemobrain Vs Dementia: Understanding the Difference

Chemobrain Vs Dementia: Understanding the Difference

4 months ago

by

Yesne Alici, MD

In a discussion with CancerNetwork®, Natalia Neparidze, MD, spoke about the importance of minimal residual disease (MRD) as a relevant end point for clinical trials assessing novel therapeutic strategies among patients with multiple myeloma.

MRD is ‘Exceedingly Helpful’ in Assessing Multiple Myeloma Disease Course

4 months ago

by

Natalia Neparidze, MD

After the FDA granted priority review to rusfertide as a potential therapeutic option for patients with polycythemia vera, CancerNetwork® spoke with Andrew Kuykendall, MD, about what a potential FDA approval would mean for these patients.

Rusfertide Approval Would Move Past ‘Archaic’ Polycythemia Vera Standard

4 months ago

by

Andrew T. Kuykendall, MD

Maha Hussain, MD, MBChB, discussed advantages associated with docetaxel-containing triplet regimens for this patients with metastatic HSPC following a Medical Crossfire session she was a presenter for.

Triplet Therapy Appears to Be Generally Well Tolerated in Metastatic HSPC

4 months ago

by

Maha Hussain, MD

Tanya Dorff, MD, discussed findings from her presentation comparing doublet and triplet regimens among patients with hormone-sensitive prostate cancer within a Medical Crossfire session held at the New York GU Cancers Congress.

Delineating Distinct Advantages With Doublet Therapy in HSPC

4 months ago

by

Tanya B. Dorff, MD

Exploring AI Use in Breast Radiation Oncology

Exploring AI Use in Breast Radiation Oncology

4 months ago

Molly Ingersoll, PhD, discussed the background behind an analysis, which assessed biological differences underlying sex- and gender-based disparities in bladder cancer outcomes.

Highlighting Sex-Based Disparities in Bladder Cancer Outcomes

4 months ago

by

Molly Ingersoll, PhD

In this GU Gemstone, Tanya Barauskas Dorff, MD, spoke with CancerNetwork at NY GU.

GU Gemstones: Tanya B. Dorff, MD

4 months ago

by

Tanya B. Dorff, MD

Sympathetic nerves actively signal to cancer-associated fibroblasts within the pancreatic tumor microenvironment, inducing a state that promotes tumor aggression.

Denervation Shows Different Pancreatic Tumor Reductions Across Sexes

4 months ago

by

Sebnem Ece Eksi, PhD

Trending on CancerNetwork

Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era

ctDNA MRD Guidance in Bladder Cancer: Pharmacy Specialist on NCCN Updates

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?